The all-in-one platform to find and track your stocks and investments
Discover the features
Statistics
Yield
-
Dividend safety
N/A
Growth score
N/A
Dividend growth last 5 y.
-
Market Cap
50 million
PE Ratio
-
Beta (volatility)
1.62
Earnings Per Share
-0.03
About
ISIN : CA03938C1041
It focuses on developing its lead drug candidate MetaBlok, which is in Phase II for the treatment or prevention of dipeptidase-1 (DPEP-1)...
Price
Performance Comparison
| Arch Biopartners Inc | |
|---|---|
| 1 year return |
-49 %
|
| 5 years return |
-29 %
|
Valuation
| Price to Book | Payout ratio | PEG Ratio |
|---|---|---|
| 0.00 | 0 % |
| Price to Sales | Price / FCF | E.V.R. |
|---|---|---|
| 53.05 |
Price–Earnings Ratio History
The Price–Earnings Ratio history is not available for this stock.
Dividend History
It looks like no dividends is being distributed for this stock...
Number of Outstanding Shares
Financials
Year-over-Year growth
Profitability
Health
News
Earnings report announcement
3/2/2026
Earnings report announcement
1/27/2026
Create a portfolio & add this stock
Add this stock and others to your own virtual portfolio and get personalised information : total annual dividends & total value, sectors breakdown, etc.
Privacy Policy • Terms and Conditions
© Copyright 2020-2026 Epsylia OÜ - All rights reserved
Moning is a platform that does not manage any funds and is purely educational. We do not provide any investment advice.
The data presented comes from different providers and may contain errors. We encourage you to always verify information through other sources.
Any financial investment involves risks including partial or total loss of capital.
The data presented comes from different providers and may contain errors. We encourage you to always verify information through other sources.
Any financial investment involves risks including partial or total loss of capital.